- Home
- CRSP vs PFSI Comparison
CRSP vs PFSI Comparison
Compare CRSP & PFSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- PFSI
- Stock Information
- Founded
- CRSP 2013
- PFSI 2008
- Country
- CRSP Switzerland
- PFSI United States
- Employees
- CRSP N/A
- PFSI N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- PFSI Finance: Consumer Services
- Sector
- CRSP Health Care
- PFSI Finance
- Exchange
- CRSP Nasdaq
- PFSI Nasdaq
- Market Cap
- CRSP 4.9B
- PFSI 5.4B
- IPO Year
- CRSP 2016
- PFSI 2013
- Fundamental
- Price
- CRSP $56.26
- PFSI $124.58
- Analyst Decision
- CRSP Buy
- PFSI Buy
- Analyst Count
- CRSP 16
- PFSI 7
- Target Price
- CRSP $72.27
- PFSI $120.14
- AVG Volume (30 Days)
- CRSP 1.9M
- PFSI 428.0K
- Earning Date
- CRSP 11-04-2025
- PFSI 10-21-2025
- Dividend Yield
- CRSP N/A
- PFSI 0.96%
- EPS Growth
- CRSP N/A
- PFSI 97.42
- EPS
- CRSP N/A
- PFSI 7.22
- Revenue
- CRSP $38,050,000.00
- PFSI $3,571,340,000.00
- Revenue This Year
- CRSP N/A
- PFSI N/A
- Revenue Next Year
- CRSP $348.18
- PFSI $23.52
- P/E Ratio
- CRSP N/A
- PFSI $17.25
- Revenue Growth
- CRSP N/A
- PFSI 65.89
- 52 Week Low
- CRSP $30.04
- PFSI $85.74
- 52 Week High
- CRSP $71.13
- PFSI $127.56
- Technical
- Relative Strength Index (RSI)
- CRSP 54.66
- PFSI 79.07
- Support Level
- CRSP $51.63
- PFSI $107.48
- Resistance Level
- CRSP $55.59
- PFSI $127.56
- Average True Range (ATR)
- CRSP 2.06
- PFSI 2.87
- MACD
- CRSP 0.27
- PFSI 1.19
- Stochastic Oscillator
- CRSP 96.36
- PFSI 85.16
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About PFSI PennyMac Financial Services Inc.
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform and integrated business focused on the production and servicing of U.S. residential mortgage loans. The company operates through two segments: production and servicing. The production segment performs loan origination, acquisition and sale activities. The servicing segment performs loan servicing for newly originated loans.